Truist Financial Issues Positive Forecast for SI-BONE (NASDAQ:SIBN) Stock Price

SI-BONE (NASDAQ:SIBN) had its target price upped by Truist Financial from $16.00 to $18.00 in a research report report published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

SIBN has been the subject of several other reports. Morgan Stanley decreased their price objective on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a research report on Wednesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $23.00.

SI-BONE Trading Down 15.9 %

Shares of SIBN stock opened at $13.14 on Wednesday. The firm has a market capitalization of $547.81 million, a PE ratio of -14.28 and a beta of 1.22. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.12 and a current ratio of 9.17. SI-BONE has a 1 year low of $11.76 and a 1 year high of $21.70. The stock has a fifty day moving average of $14.14 and a two-hundred day moving average of $14.32.

Insiders Place Their Bets

In other news, CEO Laura Francis sold 9,967 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $13.84, for a total transaction of $137,943.28. Following the sale, the chief executive officer now owns 492,923 shares in the company, valued at $6,822,054.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other SI-BONE news, CEO Laura Francis sold 9,967 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $13.84, for a total value of $137,943.28. Following the transaction, the chief executive officer now owns 492,923 shares in the company, valued at approximately $6,822,054.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Anthony J. Recupero sold 3,905 shares of SI-BONE stock in a transaction on Friday, August 16th. The shares were sold at an average price of $13.84, for a total transaction of $54,045.20. Following the sale, the insider now directly owns 238,804 shares of the company’s stock, valued at $3,305,047.36. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 25,017 shares of company stock worth $349,587. Company insiders own 3.90% of the company’s stock.

Institutional Trading of SI-BONE

Several large investors have recently made changes to their positions in SIBN. BNP Paribas Financial Markets lifted its stake in shares of SI-BONE by 24.6% in the third quarter. BNP Paribas Financial Markets now owns 106,442 shares of the company’s stock worth $1,488,000 after buying an additional 21,012 shares during the last quarter. FMR LLC boosted its holdings in SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after acquiring an additional 1,198 shares during the period. Millrace Asset Group Inc. acquired a new stake in shares of SI-BONE in the third quarter valued at about $1,056,000. Champlain Investment Partners LLC increased its stake in shares of SI-BONE by 14.7% in the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock worth $39,145,000 after purchasing an additional 358,821 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in SI-BONE by 1.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 315,092 shares of the company’s stock valued at $4,405,000 after purchasing an additional 5,966 shares during the period. Institutional investors own 98.11% of the company’s stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.